Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial

Matthias Löhr; Stephan Haas; Wolf O. Bechstein; G. Bodoky; Karel Cwiertka

doi:10.1093/annonc/mdr379

Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial

Matthias Löhr, Stephan Haas, Wolf O. Bechstein, G. Bodoky, Karel Cwiertka, Wolfgang Fischbach, Ulrich R. Fölsch, Dirk Jäger, D. Osinsky, Jana Prausová, Wolfgang E. Schmidt, Manfred P. Lutz

Elsevier BV (2011) • Volume 23, Issue 5, Pages 1214-1222

PDF Available

Quick Actions

Read Full Paper

Publication Info

DOI

10.1093/annonc/mdr379

Language

English

Topic

Pancreatic and Hepatic Oncology Research

Keywords

Medicine, Gemcitabine, Internal medicine, Chills, Pancreatic cancer, Randomized controlled trial, Chemotherapy, Adverse effect, Gastroenterology, Phases of clinical research, Oncology, Cancer, Paclitaxel, Surgery

Published

September 7, 2011

Citations

104 citations

FWCI

2.87

External Resources

DOI Link OpenAlex

Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial

Quick Actions

Publication Info

External Resources

Suggested Papers

PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer

KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease

Biofilm Producing Methicillin-Resistant Staphylococcus aureus (MRSA) Infections in Humans: Clinical Implications and Management

Suggested Papers

Suggested Papers

PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer

KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease

Biofilm Producing Methicillin-Resistant Staphylococcus aureus (MRSA) Infections in Humans: Clinical Implications and Management